

## EXPANDING ACCESS TO ESSENTIAL HEALTH CARE

We seek to bring more medicines to more people and to improve health around the world. Our social investments focus on effective and sustainable health care delivery for underserved patients, wherever they live, while empowering our colleagues, strengthening our stakeholder relationships and ultimately having a positive impact on society and our business.



---

### COMMERCIAL PROGRAMS TO IMPROVE ACCESS

We are developing a portfolio of innovative business approaches as part of our strategy to increase access to our medicines in both developed and developing countries.

#### Gavi, the Vaccine Alliance's Advance Market Commitment (AMC) for Pneumococcal Vaccines

Gavi, the Vaccine Alliance's AMC provides vaccines to the world's poorest countries on an accelerated, affordable and sustainable basis. Pfizer has committed to supply up to 740 million doses of Prevenar 13<sup>®</sup> through 2025. Prevenar 13 is available in more than 32 Gavi-eligible countries, with many additional launches planned. We are committed to helping meet the AMC's primary goal of reducing morbidity and mortality from pneumococcal disease and, specifically, to prevent an estimated seven million childhood deaths by 2030.

## ACCESS TO MEDICINES

## Helping Women Plan Their Families — Expanded Access to Sayana® Press Long-acting Contraceptive

A novel agreement with the Bill & Melinda Gates Foundation and the Children's Investment Fund Foundation will help expand access to Pfizer's long-acting contraceptive, Sayana® Press, for millions of women most in need in 69 of the world's poorest countries.

Sayana Press, a pre-filled, single-use, non-reusable injection, is a re-designed version of an injectable contraceptive from Pfizer's Global Established Pharma's (GEP) women's health portfolio. Created with the target population of women in mind, it eliminates the need to prepare a needle and syringe, allowing the contraceptive to be administered by health workers at home or in other non-medical settings.

Through this agreement and the support of a public/private sector consortium including PATH, the United Kingdom's Department for International Development, the United Nations Population Fund, and the United States Agency for International Development, Sayana Press will be sold for one U.S. dollar per dose to qualified purchasers, who can help enable the poorest women in these countries to have access to the contraceptive at reduced or no cost.



**This novel collaboration expands access to the contraceptive, Sayana® Press, in 69 of the world's poorest countries.**

Sayana® Press (medroxyprogesterone acetate) is not approved or available for use in the United States. (Photo: PATH)




**Experts have identified the need for a contraceptive method that can be administered in low resource, non-clinic settings.**

Sayana® Press (medroxyprogesterone acetate) is not approved or available for use in the United States. (Photo: PATH)



**Q: HOW DOES PFIZER MAKE SURE PEOPLE AROUND THE WORLD CAN AFFORD OUR MEDICINES?**

**INDRANIL BAGCHI**  
GLOBAL HEALTH & VALUE



**Q: WHAT PROGRAMS DOES PFIZER HAVE TO HELP PEOPLE ACCESS OUR MEDICINES GLOBALLY?**

**CAROLINE ROAN**  
CORPORATE RESPONSIBILITY

ACCESS TO MEDICINES

## BUILDING HEALTH CARE CAPACITY AROUND THE GLOBE

Weak or non-existent health care infrastructures represent a significant impediment — among the largest — to access. We continue to explore and implement models and approaches tailored to the diverse needs of patients in different geographies. Seeking holistic approaches, we work closely with governments, health organizations and other stakeholders to address the complex challenges around improving health for the underserved.



### “Last-Mile” Vaccine Coverage in Africa and Asia

The Pfizer Foundation is providing \$3 million to support demonstration projects with the goal of improving immunization coverage in Africa and Asia. The programs will focus on “last-mile” interventions to reach children in remote locations in Indonesia, Ethiopia, Malawi, Pakistan, Rwanda, Uganda and Zambia. Efforts support the United Nations Millennium Development Goal 4: to reduce under-five child mortality by two-thirds between 1990 and 2015 by building the capacity of health care systems to ensure that efficient and sustainable vaccine supplies are available to reach children who need access to vaccines. Interventions include providing health workers with mobile phones and solar-powered tablets to register children and help track vaccination schedules in real time. Short-message service (SMS) systems will be used to monitor vaccines and equipment to identify bottlenecks in the supply chain and prevent stock outs.

### Impact Investing

The Pfizer Foundation implemented a new strategy in impact investing to support social entrepreneurs and health innovators with the goal of improving health care delivery for populations at the base of the pyramid. Investments are made into funds with the intention to generate social impact alongside a potential financial return, and targeted grants will help to catalyze the pipeline of health innovators and provide technical assistance for growth. For example, we are working with the Unitus Seed Fund, which provides startup capital to enterprises that serve populations in India and Southeast Asia, and Acumen Capital Markets II, which focuses on India and East Africa.

Our investments in 2014 built on an initial investment in the Global Health Investment Fund (GHIF), a first-of-its-kind social investment fund designed to advance the development of drugs, vaccines, diagnostics and other interventions against diseases that disproportionately burden low income countries. For more information please see <http://ghif.com/>.

## Global Health Fellows

Our renowned colleague volunteer program places Pfizer colleagues in short-term assignments with international development organizations to work together to bring about meaningful and systematic improvements in health service delivery. Fellows transfer their pharmaceutical and business expertise in ways that promote access, quality and efficiency of health care. In exchange, Fellows return with experience and relationships that help inform their ability to have an impact on pressing health concerns. The Global Health Fellows program has been recognized as a “best-in-class” program model for its impact on global health, as well as its value to Pfizer colleagues and the business. To date, more than 330 colleagues have completed an estimated 330,000 hours in skills-based pro bono service, valued at more than \$50 million, with local partners throughout the developing world.

We have created Global Health Teams to expand and diversify opportunities for colleagues beyond our individual fellowships. Since 2010, more than 60 colleagues have served on cross-functional teams with 19 nonprofit organizations across six countries in Latin America. In 2014, Pfizer launched the first executive-level Global Health Team project, deploying 12 senior leaders to volunteer their expertise with a global NGO, Population Services International, with the ultimate goal of assisting this leading international development organization in advancing its public health mission.



**NIVEDITA NEHRA**  
GLOBAL  
HEALTH FELLOW

“Throughout this experience, I was constantly reminded that the word quality is not always synonymous with costly or complicated. A simple \$40 produce scale was much more efficient and cost effective in saving the lives of babies than an \$800 newborn scale that was far too expensive for most of these health care facilities. You really do return with a genuine appreciation for so many things, such as my team and company who encouraged me to embark on this amazing experience — and now produce scales have been added to that list.”



**KODJO SOROH**  
GLOBAL  
HEALTH FELLOW

“I worked with the Accorrida Global Health Foundation to establish collaborative partnerships in medical research between the West African Infectious Diseases Institute, Abuja, and 12 Nigerian universities. The institute will work to advance the fight against HIV, malaria and other infectious diseases in West Africa and bring better health care options for those in need.”

## Putting NCDs on the Global Health Agenda

We are supporting innovative approaches to enhancing capacity to prevent non-communicable diseases (NCDs) in under-resourced communities. Efforts focus on increasing community knowledge of NCD risk factors and preventive measures, such as support for quitting smoking; improving early detection and diagnosis capabilities; and, building health system capacity particularly in the primary care setting.

Learn more about innovative approaches to NCDs [here](#).



**PAUL REID**  
GIP LEAD  
COUNTRY MANAGER  
FOR IRELAND

“Pfizer is proud to support this important campaign. More than 40,000 people over the age of 50 in Ireland suffer from Atrial Fibrillation. However the vast majority of sufferers are unaware that they have it. It is a serious heart rhythm condition that can lead to serious complications. The campaign urges the public to have regular pulse checks as once the condition is detected it can be managed effectively.”



## ACCESS TO MEDICINES

### Healthy Connections

A joint effort by Pro Mujer, Mayo Clinic, Sesame Workshop and Pfizer, Healthy Connections promotes non-communicable disease prevention and family health among women and children in numerous countries across Latin America. Healthy Connections will use a new technology platform integrating mobile, web and video technology, along with remote training and access to specialists.

### WIPO Re:Search

An R&D consortium dedicated to developing new solutions — including medicines, vaccines and diagnostics — for neglected tropical diseases, malaria and tuberculosis, WIPO Re:Search was created in partnership with the World Intellectual Property Organization (WIPO), BIO Ventures for Global Health and other leaders in the R&D pharmaceutical industry. The consortium has over 90 members from 26 countries, has 85 collaborations/research agreements in place, and has facilitated eight arrangements whereby scientists from both developed and developing countries are hosted by members of WIPO Re:Search. Pfizer is involved in several agreements where we are making specific contributions to advance external research programs targeting diarrhea, dengue fever and cerebral malaria.

## GLOBAL PARTNERSHIPS TO EXPAND ACCESS

Pfizer helps expand access worldwide by working in partnership with non-governmental organizations, government agencies, multilateral aid organizations and other global health stakeholders to strengthen health care systems and improve care. Our investments also include programs that provide direct assistance, such as product donations and steep discounts, to help bridge current gaps in health care delivery to various underserved populations.

### International Trachoma Initiative (ITI)

A global program Pfizer helped to found, ITI has been working since 1998 to eliminate blinding trachoma as a public health concern. Through the ITI, we have donated more than 400 million doses of the antibiotic Zithromax® (azithromycin) to prevent and treat trachoma in support of the World Health Organization-led Global Alliance for the Elimination of Trachoma by the year 2020.

### Diflucan Partnership

Through this partnership, Pfizer provides, free of charge to government and non-governmental organizations in developing countries, Diflucan® (fluconazole) for the treatment of two fungal opportunistic infections associated with HIV and AIDS — cryptococcal meningitis and esophageal candidiasis. Since the launch of the program in 2000, Pfizer has donated over \$1.4 billion in medicine to more than 6,000 sites in 63 countries in Africa, Asia, the Caribbean and Latin America. Fifteen years into the program, Pfizer has clearly demonstrated its commitment to addressing public health issues in the developing world by helping improve the quality of life of people living with HIV and AIDS.



## ACCESS TO MEDICINES

### Pfizer Rx Pathways®

Pfizer Rx Pathways helps eligible patients in the U.S. get access to their Pfizer medicines by offering a range of support services, including insurance counseling, co-pay help, providing Pfizer medicines for free or at a savings, and more. Pfizer Rx Pathways is the latest in an array of prescription assistance programs that Pfizer has offered over the last 25 years to help eligible patients get their Pfizer medicines. For 2010–2014, the program enabled nearly 2.5 million uninsured or underinsured patients to get access to over 31 million Pfizer prescriptions. Pfizer also provides charitable donations to independent non-profit charitable organizations which support eligible patients who require help paying their out-of-pocket expenses, including co-pays or co-insurance. In 2014, Pfizer donated \$7.9 million to co-pay foundations in the U.S. dedicated to helping patients obtain the life-saving medicines they need.



**RATNA BINDRA**  
DIRECTOR  
PFIZER RX PATHWAYS

"We are actively building partnerships to spread the word on Pfizer's access programs, working with nonprofits, advocacy groups, practitioners and community health centers to help fill the gap for people who need help in getting quality health care."



## LIVING WELL AS LIFE GOES ON

For Pfizer, helping people age well is both a business priority and a social responsibility.



### GET OLD/#FOGO

In 2014, Pfizer re-launched Get Old, our multi-year reputation initiative, with a renewed focus on challenging people to face their #FOGO, or Fear Of Getting Old. This next evolution of Get Old tackles these fears head-on by bringing wit and wisdom to aging, and features new engaging content to provide insights and advice aimed at helping users to lead healthier, longer lives. The effort has led to more than 1.4 million people visiting [GetOld.com](http://GetOld.com), and a social media community of nearly 180,000 people.




**WARACHAL EILEEN  
FAISON, MD**

GET OLD CONTRIBUTOR

"Get Old empowers the community-at-large to have a conversation about what excites them about getting old and their concerns as they continue along the course of healthy aging. By discussing these issues, I believe it can help those engaged with Get Old to have an improved patient-physician dialogue. Get Old helps the community be informed, be engaged and be empowered!"

## HEALTHY AGING



## AGE-FRIENDLY CITIES

Pfizer is helping support age-friendly cities in community-based programs across the world.





## HEALTHY AGING

### Community AGEnda

Community AGEnda focuses on helping communities across the U.S. become great places to grow up and grow old. Launched in 2012 by Grantmakers In Aging with funding from the Pfizer Foundation, Community AGEnda has given grants to organizations in five communities to accelerate their age-friendly efforts. Highlights of the work in the second year of the grant include: improving mobility and walkability in areas such as Little Havana in Miami; supporting intergenerational communities in Arizona; helping families and caregivers find services in Kansas City through a new website, [linkforcare.org](http://linkforcare.org); informing regional planning efforts and advocating for affordable, accessible housing in Georgia and Indiana; and across the programs, promoting healthy lifestyles, improving access to public services and increasing volunteer, intergenerational and social opportunities. An international age-friendly photo contest challenged photographers to capture their favorite age-friendly moments. In its third year, Community AGEnda is placing particular emphasis on sustainability, seeking to embed age-friendly principles in the work of participating and partner organizations, strengthen national and international partnerships, and create informational projects to support future age-friendly efforts.

### Age-Friendly Ireland

Age-Friendly Ireland seeks to embed a sustainable network of age-friendly towns (currently, ten) across Ireland and to support a sustainable expansion that will include the continued development of resources and tools. Key learnings from 2013 and 2014 efforts include the identification of practical actions that can be introduced on an incremental basis around the country. Research and consultations with older people, service providers and community stakeholders resulted in a detailed picture of the changes that older people want and need in order to make their towns better places in which to grow old. Efforts in 2015 are focusing on enabling new towns to become age-friendly, encouraging older adults to take lead roles in enhancing their communities, and promoting the benefits of a multi-stakeholder approach to municipal planning.

### Réseau Francophone des Villes Amies des Aînés

Réseau Francophone des Villes Amies des Aînés (French Network of Age-Friendly Cities) focuses on creating and sustaining age-friendly communities throughout France and French-speaking regions of the Caribbean and the Indian Ocean. In 2014, an official guide for age-friendly cities was developed and launched with support from the Pfizer Foundation grant. Current activities include the creation of a national platform supported by ongoing media outreach to promote the need for, and value of, age-friendly cities. City-specific booklets on age-friendly initiatives, as well as stakeholder trainings, public debates, special recognition events and other communications are being developed to promote the value of age-friendly cities to the public, the business community and policy makers. Workshops and analyses focus on helping seniors to become advocates for their own needs relative to their communities.

HEALTHY AGING

## HELPAge TANZANIA COMBATING NON-COMMUNICABLE DISEASES

HelpAge International and Pfizer have worked together since 2012 to reduce the impact of non-communicable diseases (NCDs) among older people in Tanzania. During the first two years, the initiative began supporting the Government of Tanzania's efforts to provide appropriate health services to older citizens. NCDs include a range of chronic conditions, including cancer, diabetes, cardiovascular disease and hypertension, as well as Alzheimer's and other dementias. They are commonly thought of as "diseases of affluence," whereas, in reality, four-fifths of deaths from NCDs are in low- and middle-income countries and older people in developing countries are particularly at risk. Prevention through an active and healthy lifestyle can turn some of these debilitating diseases into manageable conditions.

The ongoing project focuses on developing health messaging through an intergenerational approach. It pilots a range of community-based activities aimed at promoting prevention and management of NCDs by practicing healthy lifestyles, while working with health providers at local and national levels to improve prevention, early diagnosis, follow-up and treatment of NCDs, as well as improving on data collection and analysis to inform appropriate policies. While the community-based activities are carried out in Morogoro, Kibaha and Songea districts in collaboration with organizations of older people, the curriculum reform and support to improve health information management will be undertaken together with the Ministry of Health and Social Welfare at various levels.



COMBATING NON-COMMUNICABLE DISEASES WITH INTERGENERATIONAL PROGRAMS IN TANZANIA

[READ MORE](#)



## PATIENT ENGAGEMENT

## PATIENTS AT THE CENTER

People today are able to access and exchange more information than ever before, and it's no surprise that health is an area where information-sharing is exploding. As patients become more informed, they become more involved — more active in their own care and the care of others, and in medical research.

This is the era of “patient-centricity,” where patients are far from passive subjects of study or treatment. Laypeople are taking starring roles in designing clinical trials; tracking and managing their personal health data; and, crowdsourcing new insights and solutions with diverse, far-reaching communities.

What does “patient-centricity” mean for Pfizer? “We’re sharing information with patients in ways that are more relevant for them — and importantly, we’re also listening to them and working to act on what we hear,” answers Roslyn Schneider, M.D., Pfizer’s Global Patient Affairs lead.



**ROSLYN (ROZ) F. SCHNEIDER**

SENIOR DIRECTOR  
GLOBAL PATIENT AFFAIRS

“Pfizer has always been ‘patient-centric’ in the sense of operating with patients as the heart of our focus, but now more often we’re offering patients a seat at the table — literally.”

## KIDS (KIDS AND FAMILIES IMPACTING DISEASE THROUGH SCIENCE)

The KIDS (Kids and Families Impacting Disease through Science) program invites children, adolescents and families into the research process by allowing them to serve as an advisory group to improve clinical studies for children and areas where more research is needed. KIDS, a collaboration between the American Academy of Pediatrics, children’s hospitals, local schools and other partners, including Pfizer, was piloted in 2013 in Connecticut and is expanding to other U.S. locations and abroad. Projects have included input on pediatric assent, feedback to industry researchers and formulators, collaboration with undergraduate research students, and attendance at international pediatric conferences.



**Members of the KIDS Connecticut team at the Pediatric Academic Societies Meeting in Vancouver in May 2014**



## PATIENT ENGAGEMENT

**PFIZER MEDS APP**

The Pfizer Meds app is designed to provide quick access to information for patients taking Pfizer prescription medicines. By simply scanning or entering the barcode on their prescription medicine pack, patients can access helpful, up-to-date information about their medicine and/or their medical condition. Launched in Australia and with pilots underway to expand this platform around the world, the app is available for free download in Australia from iTunes or Google Play.

**SICKLE CELL DISEASE CLINICAL TRIAL RECRUITMENT**

Sickle cell disease is a devastating illness marked by excruciating pain “crises.” Studying the disease in patients often means intercepting them at the worst of times, in emergency rooms—a big reason why sickle cell clinical trials have often been hobbled by low recruitment and retention rates. To tackle this problem, Pfizer partnered with a health care ethnography firm to “shadow” sickle cell patients in their homes and other places throughout their day to gather real-life insights. We learned more about these patients’ concerns and their strengths, what motivates them to volunteer for clinical trials, and what practices work—and do not work—for recruiting sickle cell clinical trial volunteers. These insights are being used to update Pfizer’s approach to sickle cell patient clinical trial recruitment.

“We need to show patients that we understand their point of view, and to explain better how to consider if a clinical trial may be right for them.”

— Krupa Sivamurthy, M.D., Medical Director, Sickle Cell Disease

## EMPOWERING PATIENTS

Pfizer continues to engage with patients, caregivers and the health care community through the public outreach of Chief Medical Officer, Freda Lewis-Hall, M.D. and the Pfizer Medical and research organizations. Dr. Lewis-Hall's appearances on television shows such as *Dr. Phil* and *The Doctors*, together with Pfizer medical information offered on the *Get Healthy, Stay Healthy* website, *GetOld.com* and social media, connect U.S. audiences with medical expertise, resources and useful tools to help them manage their own and their families' health.



Chief Medical Officer, Freda Lewis-Hall, M.D., appeared on *The Doctors* segment, *Breast Cancer — What You May Not Know But Should*

IN 2014, THERE WERE:

**60<sup>+</sup>** MILLION

VIEWS

OF PFIZER MEDICAL INFORMATION  
IN BROADCAST MEDIA

**13<sup>+</sup>** MILLION

VIEWS

OF PFIZER MEDICAL INFORMATION  
ONLINE



## ENVIRONMENT

## WORKING FOR A SUSTAINABLE FUTURE

At Pfizer, we recognize that embedding environmental sustainability into our business can bring significant value to our company, the people who use our products and the communities we touch.



Building on the successful achievements of our carbon emission reduction and green chemistry programs, we are working to contribute meaningfully to global efforts to reduce human impact on the environment. Throughout the lifecycle of our products, our aspiration is to further:

- reduce our carbon footprint and increase energy efficiency
- decrease dependence on limited resources
- reduce waste



ENVIRONMENT

## 2020 ENVIRONMENTAL SUSTAINABILITY GOALS\*



\*Applies to facilities within Pfizer's operational control as compared with a 2012 baseline.

In 2015, we plan to announce additional targets with the potential to drive meaningful environmental improvements across our supply chain.

Our recently revised Climate Change Position Statement can be found [here](#).

## ENVIRONMENT

## PFIZER CARES — OUR GREEN JOURNEY

Pfizer's environmental stewardship and "green journey" are guided by a sustainability program with four key components we strive to implement: optimizing processes to reduce our environmental footprint across our three goal areas; responding to our customers with innovative, sustainable packaging designs and materials; expanding sustainability efforts across our manufacturing supply chain; and increasing our understanding of our impact on the environment.

Our environmental sustainability program complements our focus on developing new therapies and delivering value. We understand that earning society's trust is essential to our company — that to continue to develop medicines that make people's lives better we must fulfill our stakeholder commitments, be accountable for conducting business responsibly, and create and sustain deep connections with all those who are touched by our work.

For a comprehensive view of our contributions to a sustainable future, see [here](#).





## ENVIRONMENT

---

**MANAGING ENVIRONMENTAL RISK**

EHS professionals at Pfizer support line management in the identification, management and mitigation of environment, health and safety risks and liabilities. Oversight of environmental compliance is governed by our Environment, Health and Safety Steering Team.

---

**PRODUCT STEWARDSHIP**

Environmental responsibility embraces the full product lifecycle. To be a true product steward, we seek to understand and effectively manage the health, safety and environmental risks during the discovery, development, manufacture, use and disposal of our products. This includes efforts to assess and address the issues associated with pharmaceuticals in the environment, encourage the proper disposal of unwanted medicines, and ensure public safety through education and awareness of sharps handling and disposal.

For more information on product stewardship, please see [here](#).

---

**PHARMACEUTICALS IN THE ENVIRONMENT**

We are committed to minimizing potential impacts on human health and the environment from the manufacture, use and disposal of our medicines. Pfizer works directly and in partnership with other member companies on trade associations such as PhRMA and EFPIA to ensure relevant science is understood and, where necessary, further advanced to help mitigate such risks.

We encourage proper disposal of unwanted medicines. Actions to reduce improper disposal of expired or unwanted prescription and non-prescription medicines lessens the potential for diversion, reduces the potential for improper use of medication, and helps protect our water. Although studies have indicated that only a small portion of medicines enter the environment through waste disposal,

**Eco Restoration Transforming Acquired Site for the Community**

Pfizer, working in concert with the local community, is restoring for beneficial use a contaminated site in North Haven, Connecticut, that came to Pfizer as part of the Pharmacia acquisition. The site has not been in use since 1993, when all manufacturing ceased and the U.S. Environmental Protection Agency began investigating the property for environmental damage caused by various chemical plants prior to Pfizer's ownership.

The restoration includes 60 acres, 17 of which are for economic development. The east side of the site is largely for public use as an ecological preserve. An open space and ecological habitat will be created on the banks of the Quinnipiac River, and an interpretative trail will be built to allow school and community groups to study the ecosystem.

At an event to commemorate the project, Senator Richard Blumenthal praised Pfizer and the town of North Haven for their perseverance on this issue and called it a "teachable moment for the entire country." Deborah Szaro, Deputy Regional Administrator, U.S. EPA Region 1, said: "There are few good neighbors left but Pfizer is one of them. The company put up \$152 million to invest in a site they acquired but didn't contaminate."

it is important to consider environmental impacts from all sources. Through education and awareness programs, Pfizer works with stakeholders to better understand the potential impacts associated with the improper disposal of unwanted medicines.

The [Pfizer Responsible Disposal Advisor](#) website debuted two years ago, and has seen encouraging usage by institutions and health care professionals. This online resource contains recommended disposal practices in the United States for all Pfizer products.



## ENVIRONMENT

## LIFECYCLE ASSESSMENT CONFIRMS REDUCED IMPACT OF SMALLER TABLET IN BLISTER PACK

With the help of Quantis, globally recognized experts in lifecycle assessment consulting, we completed a full lifecycle assessment of Pfizer's current version of Atorvastatin, also known as Lipitor.® The lifecycle assessment evaluated potential ecosystem quality impact, climate change impact, resource consumption and water usage of two tablet sizes.

Our lifecycle assessment of the smaller tablet in blister packs (available in many markets) identified the following carbon footprint reductions when compared to our larger tablet:\*

- Less materials required (42% reduction in non-active pharmaceutical ingredient raw material footprint)
- Less to ship (36% reduction in delivery footprint)
- Less packaging required (11% reduction in packaging material footprint)

In addition, we evaluated our latest manufacturing process improvements, which incorporate the principles of "green chemistry," against our original manufacturing process. Our latest innovative manufacturing process uses enzymes (bio-catalysts), water as a solvent and room temperature reactions. These changes reduced the carbon footprint of the raw materials used in our current Atorvastatin active pharmaceutical ingredient (API) manufacturing process by half when compared to our original manufacturing process.

Through the implementation of improved chemistry, introducing a smaller tablet, and reducing packaging, Pfizer has been able to reduce this product's carbon footprint and other environmental indicators as compared to when we first began making the product.

\*The API footprint is the same for both tablet sizes; these reductions are specific to the other aspects of the smaller tablet.

# 1.6

MILLION METRIC TONS CO<sub>2</sub>eq<sup>4</sup>

GREENHOUSE GAS EMISSIONS

TOTAL SCOPE 1 AND 2 GHG EMISSIONS IN  
2014 WERE 5% LOWER THAN IN 2013.

# 14

MILLION CUBIC METERS<sup>4</sup>

WATER WITHDRAWAL

TOTAL WATER WITHDRAWAL  
EXCLUDING NON-CONTACT COOLING

WATER IN 2014 WAS 9%  
LOWER THAN IN 2013.

# 106

THOUSAND METRIC TONS<sup>4</sup>

WASTE DISPOSED

TOTAL HAZARDOUS AND  
NON-HAZARDOUS WASTE  
DISPOSED IN 2014

WAS UNCHANGED FROM 2013.